Developer docs
API playgroundTry for free, no card

Search company profiles

MiNA Therapeutics

Full company profile

uuid0000yln

Namestring
MiNA Therapeutics
Legal namestring
MiNA Therapeutics Limited
Websiteurl
minatx.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

MiNA Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 and headquartered at Imperial College London's White City Campus in London, UK. The company develops small activating RNA (RNAa) therapeutics, an entirely new class of oligonucleotide medicines that restore or boost normal gene and protein function by recruiting endogenous transcriptional complexes to target genes. Its proprietary platform combines a bioinformatics discovery engine for saRNA sequence design with exclusively in-licensed SMARTICLES liposomal delivery technology, enabling advancement of new RNAa candidates from concept to clinical trial in approximately two years. The pipeline includes MTL-CEBPA (the first RNAa medicine in clinical development, evaluated in over 130 patients with advanced liver cancer and solid tumors), MTL-HBG (a preclinical in vivo therapy for sickle cell disease), and MTL-STING (a second oncology candidate).

MiNA generates revenue through research collaborations, option-to-license agreements, and milestone/royalty arrangements with major pharmaceutical partners including Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku. These partnerships span oncology, metabolic diseases, neurological disorders, and rare genetic diseases. The company has raised over $100M cumulatively across multiple funding rounds including a £23M Series A led by aMoon in 2020 and a $15M direct equity investment from Eli Lilly in 2021. Go-to-market is exclusively enterprise partnership-based — MiNA does not commercialize directly, relying on pharmaceutical partners for late-stage development and commercialization.

Short descriptiontext

MiNA Therapeutics is a clinical-stage biopharmaceutical company developing small activating RNA (RNAa) therapeutics, a novel class of oligonucleotide medicines that restore gene function. It serves pharmaceutical partners through research collaborations and licensing agreements, with lead asset MTL-CEBPA in Phase 2 development for liver cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small activating RNA therapeutics, RNAa gene activation medicines, oligonucleotide drug development, clinical-stage biotechnology pipeline, liposomal RNAa delivery
Industry6 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
RNA-based Therapeutics (saRNA / RNAa)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Research Collaborations and Licensing
TypeLicensing Royalties
Description

MiNA generates revenue through strategic research collaborations with pharmaceutical companies where partners provide funding for research activities, upfront payments, and milestone payments tied to development achievements. Examples include collaborations with Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku.

minatx.com
2Development Milestones and Royalties
TypeLicensing Royalties
Description

Collaborations typically include option fees, milestone payments upon achieving clinical and regulatory milestones, and potential royalty payments on net sales of any approved products developed through the partnership.

minatx.com
3Equity Investment
TypeSubscription Recurring
Description

The company has raised significant equity financing including Series A funding and direct investments from pharmaceutical partners like Lilly's $15m equity investment and Sosei's £35m strategic investment.

minatx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MiNA Therapeutics develops a proprietary pipeline of small activating RNA (RNAa) therapeutics — an entirely new class of oligonucleotide medicines that restore or boost normal gene expression at the transcriptional level. Its clinical-stage assets include MTL-CEBPA (cancer immunotherapy combination), MTL-HBG (sickle cell disease) and MTL-STING (cancer immunotherapy), supported by an in-house bioinformatics discovery engine and the in-licensed SMARTICLES liposomal delivery platform. MiNA commercializes these assets primarily through research collaborations, option-to-license and co-development agreements with large pharmaceutical partners such as Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin and Nippon Shinyaku.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MTL-CEBPA demonstrated acceptable safety profile and potential synergistic efficacy in Phase I liver cancer trial with five patients experiencing objective tumour responses including two complete responses.
+3 more records
Product overview1 text field

MiNA Therapeutics is the global leader in small activating RNA (RNAa) therapeutics, developing a proprietary pipeline of new medicines with an initial focus on genetic medicine. The company's core product portfolio includes MTL-CEBPA (the first RNAa medicine to achieve clinical Proof of Platform, evaluated in over 130 patients), MTL-HBG (an in vivo therapy for sickle cell disease in pre-clinical development), and MTL-STING (a second pipeline candidate for cancer immunotherapy). The RNAa Platform underlies all programs, combining a bioinformatics discovery engine for designing saRNA therapeutics with SMARTICLES liposomal delivery technology. The company collaborates with leading pharmaceutical partners including Lilly, BioMarin, Nippon Shinyaku, AstraZeneca, Boehringer Ingelheim, and Servier to apply its technology platform across therapeutic areas including cancer, metabolic diseases, and rare genetic diseases.

Product and service4 records
1MTL-CEBPA
CategoryClinical-stage oncology candidate (saRNA)
Description

First-in-class small activating RNA (saRNA) therapeutic designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels. Developed as a combination therapy in cancer, evaluated in over 130 subjects including 80 patients with advanced liver cancer and 50 patients with advanced solid tumor malignancies. The first RNAa medicine to demonstrate clinical Proof of Platform.

2MTL-HBG
CategoryPre-clinical rare disease candidate (saRNA)
Description

Investigational in vivo saRNA therapy for Sickle Cell Disease (SCD) and beta-thalassemia. MTL-HBG increases transcription of the HBG gene, enabling patients to produce enhanced levels of fetal hemoglobin (HbF) without the need for preconditioning or complex cell engineering. Delivered using the NOV340 liposomal formulation, with NHP data showing delivery to greater than 60% of committed erythroid progenitors. Currently in pre-clinical development.

3MTL-STING
CategoryPre-clinical cancer immunotherapy candidate (saRNA)
Description

Second drug candidate advanced from MiNA's internal pipeline of saRNA therapeutics. MTL-STING is designed to overcome the downregulation of STING in myeloid cells, a highly validated drug target that plays a key role in immune evasion in cancer.

4RNAa Discovery Platform
CategoryLicensed therapeutic discovery platform (RNAa)
Description

Proprietary small activating RNA (RNAa) discovery and development platform combining an in-house bioinformatics engine for designing saRNA sequences with the SMARTICLES liposomal delivery technology. Offered to pharmaceutical partners via research collaborations, option-to-license and co-development agreements across oncology, metabolic disease, neurological disorders and rare genetic diseases.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Nippon Shinyaku
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-04
Description

Research collaboration to develop RNAa therapeutics targeting rare neurodegenerative diseases. Collaboration includes licensing agreement option based on early-stage preclinical outcomes.

minatx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-24
Description

Multi-target research collaboration and option licensing agreement for discovery and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

Investigator-sponsored Phase 1 study of MTL-CEBPA in combination with first-line standard of care (atezolizumab and bevacizumab) in patients with previously untreated, advanced hepatocellular carcinoma. F. Hoffmann-La Roche supporting the study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-11
Description

Global research collaboration to develop novel drug candidates using MiNA's proprietary saRNA technology platform. MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly also made a $15m equity investment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-12
Description

Pre-clinical research collaboration combining studies with Wistar Institute on immunological effects of MTL-CEBPA and benefits in combination with other cancer therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-20
Description

Research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-07
Description

Research collaboration to evaluate small activating RNA (saRNA) molecules in metabolic diseases. Combines MiNA's expertise in saRNA discovery with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Collaboration with investigators at the University of Liverpool on the up-regulation of gene targets using saRNA technology.

9Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-11-08
Description

Collaboration and licensing agreement focused on development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's saRNA therapeutics platform.

minatx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Multi-year collaborative research agreement to discover and develop new saRNA medicines. MiNA is based at Imperial College London's White City Campus.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-01-01
Description

Ongoing collaboration with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds. Founder Pål Sætrom is Professor of Bioinformatics at NTNU.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in RNA interference (siRNA) therapeutics with multiple approved products. Operates in an adjacent oligonucleotide RNA therapeutic class to MiNA's RNAa platform and is the most established comparable for any RNA-based biotech business model.

TypeBroad incumbent
Description

Pioneer in antisense oligonucleotide (ASO) therapeutics with a deep clinical pipeline and multiple approved products. Comparable to MiNA in using synthetic oligonucleotides to modulate gene expression and in the breadth of partnered programs across therapeutic areas.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company using siRNA and targeted RNAi delivery platforms. Closely comparable to MiNA in technology modality (oligonucleotide-based gene modulation), business model (broad pharma partnerships), and pipeline breadth across rare and metabolic diseases.

TypeDirect peer
Description

Oligonucleotide RNAi therapeutic developer (acquired by Novo Nordisk) and co-founded by MiNA co-founder John Rossi. Direct comparable in oligonucleotide modality, GalNAc-delivery approach, and partnership-driven commercialization model.

TypeDirect peer
Description

China-based clinical-stage developer of small activating RNA (saRNA) therapeutics — the same modality as MiNA. Co-founded by Robert Place (now MiNA's CTO), making Ractigen the most direct small-activating-RNA competitor globally.

TypeDirect peer
Description

Clinical-stage oligonucleotide therapeutics company using PRISM platform for stereopure ASOs and siRNAs. Comparable to MiNA in oligonucleotide modality, pipeline targeting rare genetic and neurological diseases, and partnership-heavy development model.

TypeEmerging player
Description

Clinical-stage developer of antisense oligonucleotide therapeutics that upregulate protein expression (TANGO approach). Mechanistically adjacent to MiNA's RNAa platform — both aim to upregulate endogenous gene expression — and Stoke's focus on severe genetic diseases (including a sickle cell/beta-thalassemia program) directly overlaps MiNA's MTL-HBG opportunity.

TypeEmerging player
Description

Clinical-stage RNA editing company developing Axiomer platform for ADAR-mediated RNA editing. Adjacent comparator to MiNA as a next-generation RNA therapeutic platform targeting genetic diseases with an oligonucleotide-based approach.

9Translate Bio (acquired by Sanofi)
TypeBroad incumbent
Description

mRNA therapeutics developer (acquired by Sanofi in 2021) with a comparable RNA-based modality and pipeline spanning rare diseases and vaccines. Useful benchmark for RNA platform M&A valuations.

TypeOthers
Description

Clinical-stage immunology-focused biotech that has explored RNA interference approaches in infectious disease. Comparable in being a private-equity and pharma-partnered biotech business model, though operating in a different therapeutic area.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MiNA Therapeutics

RNA-based Therapeutics (saRNA / RNAa)minatx.com

MiNA Therapeutics is a clinical-stage biopharmaceutical company developing small activating RNA (RNAa) therapeutics, a novel class of oligonucleotide medicines that restore gene function. It serves pharmaceutical partners through research collaborations and licensing agreements, with lead asset MTL-CEBPA in Phase 2 development for liver cancer.

What MiNA Therapeutics does

MiNA Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 and headquartered at Imperial College London's White City Campus in London, UK. The company develops small activating RNA (RNAa) therapeutics, an entirely new class of oligonucleotide medicines that restore or boost normal gene and protein function by recruiting endogenous transcriptional complexes to target genes. Its proprietary platform combines a bioinformatics discovery engine for saRNA sequence design with exclusively in-licensed SMARTICLES liposomal delivery technology, enabling advancement of new RNAa candidates from concept to clinical trial in approximately two years. The pipeline includes MTL-CEBPA (the first RNAa medicine in clinical development, evaluated in over 130 patients with advanced liver cancer and solid tumors), MTL-HBG (a preclinical in vivo therapy for sickle cell disease), and MTL-STING (a second oncology candidate).

MiNA generates revenue through research collaborations, option-to-license agreements, and milestone/royalty arrangements with major pharmaceutical partners including Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku. These partnerships span oncology, metabolic diseases, neurological disorders, and rare genetic diseases. The company has raised over $100M cumulatively across multiple funding rounds including a £23M Series A led by aMoon in 2020 and a $15M direct equity investment from Eli Lilly in 2021. Go-to-market is exclusively enterprise partnership-based — MiNA does not commercialize directly, relying on pharmaceutical partners for late-stage development and commercialization.

MiNA Therapeutics firmographics

Firmographics
Name
MiNA Therapeutics
Legal name
MiNA Therapeutics Limited
Website
https://minatx.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
MiNA Therapeutics is a clinical-stage biopharmaceutical company developing small activating RNA (RNAa) therapeutics, a novel class of oligonucleotide medicines that restore gene function. It serves pharmaceutical partners through research collaborations and licensing agreements, with lead asset MTL-CEBPA in Phase 2 development for liver cancer.
Ownership category
akta.pro rank

MiNA Therapeutics industry classification

Industry
Product category
RNA-based Therapeutics (saRNA / RNAa)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Small activating RNA therapeutics
  • RNAa gene activation medicines
  • Oligonucleotide drug development
  • Clinical-stage biotechnology pipeline
  • Liposomal RNAa delivery

Where MiNA Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

MiNA Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Research Collaborations and Licensing: MiNA generates revenue through strategic research collaborations with pharmaceutical companies where partners provide funding for research activities, upfront payments, and milestone payments tied to development achievements. Examples include collaborations with Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin, and Nippon Shinyaku.
  2. Development Milestones and Royalties: Collaborations typically include option fees, milestone payments upon achieving clinical and regulatory milestones, and potential royalty payments on net sales of any approved products developed through the partnership.
  3. Equity Investment: The company has raised significant equity financing including Series A funding and direct investments from pharmaceutical partners like Lilly's $15m equity investment and Sosei's £35m strategic investment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MiNA Therapeutics product offering

Product offering

Core offering

MiNA Therapeutics develops a proprietary pipeline of small activating RNA (RNAa) therapeutics — an entirely new class of oligonucleotide medicines that restore or boost normal gene expression at the transcriptional level. Its clinical-stage assets include MTL-CEBPA (cancer immunotherapy combination), MTL-HBG (sickle cell disease) and MTL-STING (cancer immunotherapy), supported by an in-house bioinformatics discovery engine and the in-licensed SMARTICLES liposomal delivery platform. MiNA commercializes these assets primarily through research collaborations, option-to-license and co-development agreements with large pharmaceutical partners such as Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin and Nippon Shinyaku.

Product overview

MiNA Therapeutics is the global leader in small activating RNA (RNAa) therapeutics, developing a proprietary pipeline of new medicines with an initial focus on genetic medicine. The company's core product portfolio includes MTL-CEBPA (the first RNAa medicine to achieve clinical Proof of Platform, evaluated in over 130 patients), MTL-HBG (an in vivo therapy for sickle cell disease in pre-clinical development), and MTL-STING (a second pipeline candidate for cancer immunotherapy). The RNAa Platform underlies all programs, combining a bioinformatics discovery engine for designing saRNA therapeutics with SMARTICLES liposomal delivery technology. The company collaborates with leading pharmaceutical partners including Lilly, BioMarin, Nippon Shinyaku, AstraZeneca, Boehringer Ingelheim, and Servier to apply its technology platform across therapeutic areas including cancer, metabolic diseases, and rare genetic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • MTL-CEBPA First-in-class small activating RNA (saRNA) therapeutic designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels. Developed as a combination therapy in cancer, evaluated in over 130 subjects including 80 patients with advanced liver cancer and 50 patients with advanced solid tumor malignancies. The first RNAa medicine to demonstrate clinical Proof of Platform.
  • MTL-HBG Investigational in vivo saRNA therapy for Sickle Cell Disease (SCD) and beta-thalassemia. MTL-HBG increases transcription of the HBG gene, enabling patients to produce enhanced levels of fetal hemoglobin (HbF) without the need for preconditioning or complex cell engineering. Delivered using the NOV340 liposomal formulation, with NHP data showing delivery to greater than 60% of committed erythroid progenitors. Currently in pre-clinical development.
  • MTL-STING Second drug candidate advanced from MiNA's internal pipeline of saRNA therapeutics. MTL-STING is designed to overcome the downregulation of STING in myeloid cells, a highly validated drug target that plays a key role in immune evasion in cancer.
  • RNAa Discovery Platform Proprietary small activating RNA (RNAa) discovery and development platform combining an in-house bioinformatics engine for designing saRNA sequences with the SMARTICLES liposomal delivery technology. Offered to pharmaceutical partners via research collaborations, option-to-license and co-development agreements across oncology, metabolic disease, neurological disorders and rare genetic diseases.

Quantifiable outcome

  • MTL-CEBPA demonstrated acceptable safety profile and potential synergistic efficacy in Phase I liver cancer trial with five patients experiencing objective tumour responses including two complete responses.
  • +3 more outcomes

Companies that use MiNA Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

MiNA Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

MiNA Therapeutics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Nippon ShinyakucoreStrategic or Co-development Partner · 4 April 2024Research collaboration to develop RNAa therapeutics targeting rare neurodegenerative diseases. Collaboration includes licensing agreement option based on early-stage preclinical outcomes.
  • BioMarin PharmaceuticalcoreStrategic or Co-development Partner · 24 April 2023Multi-target research collaboration and option licensing agreement for discovery and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases.
  • National University Cancer Institute, Singapore (NCIS)minorStrategic or Co-development Partner · 1 December 2021Investigator-sponsored Phase 1 study of MTL-CEBPA in combination with first-line standard of care (atezolizumab and bevacizumab) in patients with previously untreated, advanced hepatocellular carcinoma. F. Hoffmann-La Roche supporting the study.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 11 May 2021Global research collaboration to develop novel drug candidates using MiNA's proprietary saRNA technology platform. MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly also made a $15m equity investment.
  • The Wistar InstituteminorStrategic or Co-development Partner · 12 April 2021Pre-clinical research collaboration combining studies with Wistar Institute on immunological effects of MTL-CEBPA and benefits in combination with other cancer therapies.
  • ServiercoreStrategic or Co-development Partner · 20 January 2021Research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
  • AstraZenecacoreStrategic or Co-development Partner · 7 January 2020Research collaboration to evaluate small activating RNA (saRNA) molecules in metabolic diseases. Combines MiNA's expertise in saRNA discovery with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
  • University of LiverpoolminorStrategic or Co-development Partner · 1 January 2018Collaboration with investigators at the University of Liverpool on the up-regulation of gene targets using saRNA technology.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 8 November 2017Collaboration and licensing agreement focused on development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's saRNA therapeutics platform.
  • Imperial College LondoncoreStrategic or Co-development Partner · 1 January 2015Multi-year collaborative research agreement to discover and develop new saRNA medicines. MiNA is based at Imperial College London's White City Campus.
  • NTNU TrondheimcoreTechnology or Integration · 1 January 2014Ongoing collaboration with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds. Founder Pål Sætrom is Professor of Bioinformatics at NTNU.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

MiNA Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Alnylam Pharmaceuticals: Global leader in RNA interference (siRNA) therapeutics with multiple approved products. Operates in an adjacent oligonucleotide RNA therapeutic class to MiNA's RNAa platform and is the most established comparable for any RNA-based biotech business model.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with a deep clinical pipeline and multiple approved products. Comparable to MiNA in using synthetic oligonucleotides to modulate gene expression and in the breadth of partnered programs across therapeutic areas.
  • Translate Bio (acquired by Sanofi): mRNA therapeutics developer (acquired by Sanofi in 2021) with a comparable RNA-based modality and pipeline spanning rare diseases and vaccines. Useful benchmark for RNA platform M&A valuations.

Direct peers

  • Arrowhead Pharmaceuticals: Clinical-stage RNA therapeutics company using siRNA and targeted RNAi delivery platforms. Closely comparable to MiNA in technology modality (oligonucleotide-based gene modulation), business model (broad pharma partnerships), and pipeline breadth across rare and metabolic diseases.
  • Dicerna Pharmaceuticals: Oligonucleotide RNAi therapeutic developer (acquired by Novo Nordisk) and co-founded by MiNA co-founder John Rossi. Direct comparable in oligonucleotide modality, GalNAc-delivery approach, and partnership-driven commercialization model.
  • Ractigen Therapeutics: China-based clinical-stage developer of small activating RNA (saRNA) therapeutics — the same modality as MiNA. Co-founded by Robert Place (now MiNA's CTO), making Ractigen the most direct small-activating-RNA competitor globally.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company using PRISM platform for stereopure ASOs and siRNAs. Comparable to MiNA in oligonucleotide modality, pipeline targeting rare genetic and neurological diseases, and partnership-heavy development model.

Emerging players

  • Stoke Therapeutics: Clinical-stage developer of antisense oligonucleotide therapeutics that upregulate protein expression (TANGO approach). Mechanistically adjacent to MiNA's RNAa platform — both aim to upregulate endogenous gene expression — and Stoke's focus on severe genetic diseases (including a sickle cell/beta-thalassemia program) directly overlaps MiNA's MTL-HBG opportunity.
  • ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer platform for ADAR-mediated RNA editing. Adjacent comparator to MiNA as a next-generation RNA therapeutic platform targeting genetic diseases with an oligonucleotide-based approach.

Others

  • Vir Biotechnology: Clinical-stage immunology-focused biotech that has explored RNA interference approaches in infectious disease. Comparable in being a private-equity and pharma-partnered biotech business model, though operating in a different therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MiNA Therapeutics social profiles

Digital presence

MiNA Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MiNA Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

MiNA Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MiNA Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiNA Therapeutics

What does MiNA Therapeutics do?

MiNA Therapeutics develops a proprietary pipeline of small activating RNA (RNAa) therapeutics — an entirely new class of oligonucleotide medicines that restore or boost normal gene expression at the transcriptional level. Its clinical-stage assets include MTL-CEBPA (cancer immunotherapy combination), MTL-HBG (sickle cell disease) and MTL-STING (cancer immunotherapy), supported by an in-house bioinformatics discovery engine and the in-licensed SMARTICLES liposomal delivery platform. MiNA commercializes these assets primarily through research collaborations, option-to-license and co-development agreements with large pharmaceutical partners such as Eli Lilly, AstraZeneca, Boehringer Ingelheim, Servier, BioMarin and Nippon Shinyaku.

Is MiNA Therapeutics a public or private company?

MiNA Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was MiNA Therapeutics founded?

MiNA Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is MiNA Therapeutics based?

MiNA Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does MiNA Therapeutics make money?

Three revenue lines are on record. Research Collaborations and Licensing is the primary driver. The others are development Milestones and Royalties and equity Investment.

Who are MiNA Therapeutics's main competitors?

Broad incumbents on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Translate Bio (acquired by Sanofi). Direct peers are Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ractigen Therapeutics and Wave Life Sciences. Emerging players are Stoke Therapeutics and ProQR Therapeutics. Vir Biotechnology is listed as an others.

Does MiNA Therapeutics have an API?

No public API is recorded for MiNA Therapeutics.

What industry is MiNA Therapeutics in?

MiNA Therapeutics's product category is RNA-based Therapeutics (saRNA / RNAa). Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaRNA therapeuticsThis article provides a comprehensive overview of RNA therapeutics, detailing the mechanisms and clinical applications of various RNA-based medications such as mRNA, antisense RNA, and siRNA. It highlights significant developments including the global deployment of mRNA vaccines for COVID-19 by companies like Pfizer-BioNTech and Moderna, as well as ongoing research into cancer immunotherapy and tissue regeneration. The text also outlines the scientific history, delivery challenges, and specific therapeutic candidates currently in clinical trials.Business Wire BlogRNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP Therapeutics -The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a 68% CAGR. Over 100 next-generation RNA therapies are in development, with 75% still in discovery or preclinical stages, and investors have poured nearly USD 2.9 billion in the past four years.PR NewswireNS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous SystemNippon Shinyaku, parent of NS Pharma, entered a joint research agreement with MiNA Therapeutics to develop nucleic acid drugs for rare central nervous system diseases. MiNA will provide RNAa therapeutics, and Nippon Shinyaku will have an option to exclusively develop candidates with milestone and royalty payments.Business Wire BlogMiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic DiseasesMiNA Therapeutics and BioMarin Pharmaceutical announced a multi-target research collaboration and option licensing agreement to develop RNAa therapeutics for rare genetic diseases. BioMarin will use MiNA's RNAa platform to identify candidates, with an upfront payment and future royalties, though financial terms were not disclosed. The deal excludes oncology and other areas outside genetic disease.PR NewswireGrowth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing 2022The report from Research and Markets highlights growth opportunities in gene editing technologies, advanced RNA therapeutics, antibody drug conjugates, and biomanufacturing. It features recent innovations and various companies involved in developing new therapies and tools for the life sciences industry. This edition provides insights into targeted and efficient genetic engineering advancements, particularly in therapeutic applications.BioSpaceMiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of GrowthMiNA Therapeutics expanded its senior leadership team with four new hires, including Troels Koch as Senior Vice President of Chemistry. The appointments aim to support the company's next phase of growth and advance its pipeline of new medicines through clinical development.ForbesThe U.K. Genomics Startups Changing The Future Of Healthcare ForeverThe U.K. genomics industry, worth over £5 billion, is highlighted by startups like Saphetor, Genomics plc, Sano Genetics, and MiNA Therapeutics. These companies use genomic data for disease diagnosis, risk prediction, and drug discovery, with funding ranging from pre-seed to Series A rounds.YahooLilly, MiNA Ink Broad RNA Deal Worth $1.25BEli Lilly and MiNA Therapeutics agreed to develop small activating RNA candidates against up to five targets, with Lilly paying $25 million upfront and milestones up to $245 million per target. MiNA will receive tiered royalties on product sales. Lilly is already active in RNA therapeutics with other partners.BenzingaLilly, MiNA Ink Broad RNA Deal Worth $1.25B - Eli Lilly (NYSE:LLY), Atrium Therapeutics (NASDAQ:RNA)Eli Lilly has entered into a broad collaboration agreement with MiNA Therapeutics to develop small activating RNA (saRNA) candidates against up to five targets. The deal includes a $25 million upfront payment, potential milestone payments of up to $245 million per target, and tiered royalties on future product sales. This partnership expands Eli Lilly's existing RNA therapeutics platform by leveraging MiNA's specialized technology.PR NewswireLilly and MiNA Therapeutics Announce saRNA Research CollaborationEli Lilly and Company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform, covering up to five targets selected by Lilly across key therapeutic areas. MiNA will receive a $25 million upfront payment and is eligible for potential development and commercialization milestones up to $245 million per target, plus tiered royalties from low-single to low-double digits on product sales, while Lilly will handle preclinical and clinical development and retain exclusive commercialization rights. The collaboration validates MiNA's saRNA platform while expanding Lilly's RNA therapeutics capabilities into new targets and therapeutic areas.